0001690585-26-000006
SEC filingDianthus Therapeutics, Inc. reported a net loss of $162.3 million for the fiscal year ended December 31, 2025, compared to a net loss of $84.9 million in the prior year. Total revenues were $2.0 million, a significant decrease from $6.2 million in 2024, primarily due to reduced reimbursable costs from license agreements. Operating expenses increased to $180.0 million from $108.1 million, driven by a $62.5 million rise in research and development costs for clinical trials of claseprubart and the DNTH212 program, and a $9.3 million increase in general and administrative expenses. The company ended the year with $514.4 million in cash, cash equivalents, and investments, which it believes is sufficient to fund operations into 2028.
Dianthus Therapeutics, Inc. (DNTH) is a clinical-stage biotechnology company with no product revenue. For the fiscal year ended December 31, 2025, the company reported a total comprehensive loss of $162.0 million, which includes a net loss of $162.3 million and other comprehensive income of $0.4 million. This represents a significant increase in net loss compared to the $85.0 million net loss reported for the fiscal year 2024. The increase in loss is primarily attributable to a substantial rise in operating expenses, which grew to $180.0 million from $108.1 million in the prior year. This was partially offset by a decrease in total revenues to $2.0 million from $6.2 million. The company's financial performance reflects its ongoing investment in clinical development programs.
The company's total revenues of $2.0 million for FY 2025 consist entirely of license revenue from collaboration agreements. This represents a decrease of $4.2 million from the $6.2 million in total revenues recognized in FY 2024. The decrease is primarily due to a reduction in reimbursable costs associated with the claseprubart clinical trials under the Tenacia Agreements, which replaced the former Zenas Agreements. In FY 2025, the company recognized $2.0 million in license revenue from the Tenacia Agreements, compared to $0.3 million in FY 2024. It recognized $0 in related party license revenue in FY 2025, compared to $5.9 million in FY 2024 from the Zenas Agreements. The company does not generate revenue from product sales and does not expect to do so in the foreseeable future.
The company reported a loss from operations of $177.9 million for FY 2025, compared to a loss from operations of $101.9 million in FY 2024. The operating loss margin, calculated as loss from operations as a percentage of total revenues, is not a meaningful metric given the nominal revenue base and clinical-stage nature of the business. The significant increase in operating loss is driven by escalated research and development (R&D) and general and administrative (G&A) expenses. R&D expenses increased by $62.5 million (75%) to $145.6 million, primarily due to increased clinical trial activities for claseprubart and a $30.0 million upfront and milestone payment for the DNTH212 program. G&A expenses increased by $9.3 million (37%) to $34.3 million, driven by personnel and stock-based compensation costs to support the expanding clinical operations.
Net cash used in operating activities was $129.1 million for FY 2025, compared to $78.2 million used in FY 2024. The increase in cash burn is consistent with the expanded clinical development activities. Net cash used in investing activities was $122.8 million, primarily for purchases of investment securities. Net cash provided by financing activities was $280.1 million, largely from a public offering. As of December 31, 2025, the company held $514.4 million in cash, cash equivalents, and investments ($51.1M cash, $353.2M short-term investments, $110.1M long-term investments). Total assets were $530.9 million, with total liabilities of $37.5 million, resulting in total stockholders' equity of $493.4 million. The company believes its current cash resources are sufficient to fund operations into 2028.
Management's strategy focuses on advancing its clinical-stage candidates. Key priorities include initiating a global Phase 3 trial for claseprubart in generalized myasthenia gravis (gMG) in mid-2026, continuing enrollment in the Phase 3 trial for chronic inflammatory demyelinating polyneuropathy (CIDP) and the Phase 2 trial for multifocal motor neuropathy (MMN), and advancing DNTH212. The company anticipates top-line results from the Phase 2 MMN trial in the second half of 2026 and from the Phase 3 gMG trial in the second half of 2028. It will require substantial additional capital to complete development and build commercialization infrastructure. Future funding may come from equity or debt financings, collaborations, or licensing arrangements. The company faces risks common to clinical-stage biotech firms, including clinical trial failures, regulatory hurdles, and intense competition.